NEOS S&P 500 High Income ETF (SPYI) Stock Price Today
Aura AI Summary
Key Stats
- $12.50BMarket Cap
- 3,058,962Volume
- Income / Options OverlaySector
- $54.4252W High
- $47.9852W Low
- 58 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 32% Sell | 68% BuyTrading Activity
Track NEOS S&P 500 High Income ETF (SPYI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, NEOS S&P 500 High Income ETF has traded between a low of $47.98 and a high of $54.42, highlighting its annual price range. Buy and sell NEOS S&P 500 High Income ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Most Recent News
ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...

Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.
The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...

New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.
MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.